drugset / Trial / NCT06315530
Effect of Telitacicept on Antibody Titers in Primary APS Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2025-04-30
- Completion
- 2026-01-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |
| Background | Aspirin | Small molecule | — | — |